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Dramatic Response to Low-Dose Erlotinib of Epidermal
Growth Factor Receptor Mutation-Positive Recurrent
Non-small Cell Lung Cancer After Severe Cutaneous Toxicity
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Abstract: Erlotinib is increasingly being used for the treatment of
non-small cell lung cancer. The recommended dose is 150 mg/day and
no efficacy data is available for lower doses. We describe a case of
dramatic tumor response to 50 mg erlotinib in a patient with EGFR
mutation positive NSCLC who developed a severe rash on full dose
erlotinib. Rash is known to correlate with response and survival in
patients treatedwith erlotinib.Our case suggests that in the presence of rash,
dose reductions to “subtherapeutic” levels remain effective and may pre-
vent unnecessary early treatment termination.
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The epidermal growth factor receptor (EGFR) tyrosinekinase inhibitor erlotinib is approved for patients with
non-small cell lung cancer (NSCLC) who have failed 1
platinum-based chemotherapy regimen. The standard dose is
150 mg/d. When severe or intolerable toxicity occurs, dose
reductions to 100 mg/d are recommended. There are no data
available on the efficacy of lower doses. We describe a case
of impressive response of recurrent, EGFR mutation-positive
NSCLC to erlotinib 50 mg/d.
CASE HISTORY
In June 2006, a 46-year-old Caucasian never-smoker pre-
sented with stage IIIb adenocarcinoma of the left upper lobe. She
received six cycles of paclitaxel/carboplatin. In June 2007, she
developed progressive disease with multiple liver, bone, and
brain metastases. In view of the clinical characteristics predict-
ing a good response, she started erlotinib 150 mg/d. However,
because of a severe, grade 4 generalized papulopustular rash,
treatment was discontinued after 7 days (Figure 1A). Subse-
quently, she completed six cycles of gemcitabine/cisplatin and
four cycles of pemetrexed. In August 2008, a follow-up com-
puted tomography (CT) scan showed new intrapulmonary and
intracerebral metastases. Because of the lack of other alterna-
tives, we again offered her erlotinib treatment but at a reduced
dose (50 mg/d). This was well tolerated with toxicity limited to
a grade 2 papulopustular rash on the face (Figure 1B). After 6
weeks of therapy, a CT scan showed marked response (Figure
2). Molecular analysis of a biopsy from a pleural metastasis
demonstrated an EGFR L858R mutation in exon 21. The erlo-
tinib steady-state plasma concentration was 0.352 g/L. Cyto-
chrome P450 (CYP) genotyping revealed no polymorphisms.
Currently, she continues on this treatment regimen.
DISCUSSION
This is the first report of response to one third of the
recommended dose of erlotinib. At 50 mg/d, the erlotinib
steady-state plasma concentration was 0.352 g/ml. This is
significantly lower than the estimated 0.5 g/ml needed for
clinical efficacy.1 Although erlotinib is metabolized by CYP
enzymes, our patient neither had CYP polymorphisms nor
was taking CYP-inducing comedications. Consistent with the
clinical characteristics of female gender, a negative smoking
history, and adenocarcinoma histology, an EGFR mutation in
exon 21 was detected in a biopsy from a pleural metastasis.
This mutation is associated with improved response to EGFR
tyrosine kinase inhibitor therapy.2
Patients receiving EGFR inhibitors frequently develop
the typical rash characterized by inflammatory papules and
pustules demonstrated in our patient.3 The presence and
severity of this rash correlate with response and survival.4,5
Our patient developed a severe, generalized erlotinib-induced rash
at the standard dose of 150 mg/d. After treatment discontinuation,
this resolved completely. On rechallengewith a lower dose, the rash
reappeared but was mild and tolerable. Currently, studies are as-
sessing whether dose escalation to rash improves outcome in pa-
tients who do not initially develop a rash. However, no studies are
investigating the effect of dose reductions on antitumor efficacy in
patients who develop a severe rash. Our case suggests that in
patients with EGFR mutation-positive NSCLC who develop a
high-grade rash, erlotinib dose reductions to “subtherapeutic” levels
remain effective while improving the severity of the rash.
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FIGURE 1. Photography images of the face
show a severe (grade 4) erlotinib-induced
papulopustular rash on erlotinib 150 mg/d
(A), which improved to grade 2 on erlotinib
50 mg/d (B).
FIGURE 2. Radiologic images before and 6 weeks after erlotinib 50 mg/d. Axial, contrast-enhanced computed tomographic
(CT) images of the lungs show a right-sided pleural effusion and multiple intrapulmonary metastases bilaterally (arrows) (A),
which shrunk or disappeared after 6 weeks of treatment (B). Axial, contrast-enhanced CT images of the abdomen show two
liver metastases (arrows) (C), which decreased significantly in size (D).
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